Direct patent infringement CAR-T cells, Part 2

The high costs associated with modifying and producing CAR-T cells for use in cancer patients have caused considerable controversy among medical practitioners and patient organizations in Europe, including the European non-governmental organization Public Eye, who successfully opposed patent EP’091 before the European Patent Office.